- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04078555
A Study to Evaluate ENERGI-F703 GEL in Venous Leg Ulcer
A Randomized, Double-Blind, Placebo-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Venous Leg Ulcer (VLU)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Yifang Cheng, PhD
- Phone Number: 701 +886-2-2627-0835
- Email: yf@energenesis-biomedical.com
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- Shin Kong Wu Ho-Su Memorial Hospital
-
Contact:
- Cha-Chun Chen, MD
-
Principal Investigator:
- Cha-Chun Chen, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- With either gender aged at least 20 years old
- With venous reflux >0.1 sec measured by duplex ultrasound imaging dated within 6 months prior to the Screening visit
- With at least one venous ulcer on the lower leg (knee to ankle inclusive) and not healing for at least 4 weeks. The ulcer with the largest surface area will be selected as target ulcer. If two or more ulcers have the largest size, the one with the longest duration will be selected
- With the target ulcer size of 2 cm2 to 50 cm2
- Target VLU involves a full thickness skin loss, but without exposure of tendon, muscle, or bone
- Target VLU should be free of any necrosis or infection in any soft tissue and bone tissue
- Able to tolerate compression therapy
- Subject has signed the written informed consent form
Exclusion Criteria:
- Target VLU With active cellulitis or osteomyelitis
- With target ulcer size decreased by at least 30% after 2 weeks of standard care
- With poor nutritional status (albumin < 2g/dl), poor diabetic control (HbA1c > 12%), a leukocyte counts < 2,000/mm3, abnormal liver function (AST, ALT>3 × upper limit of normal range) tests within 14 days prior to Screening visit or 28 days prior to Randomization visit
- Requiring treatment with chemotherapeutic agents
- With known or suspected hypersensitivity to any ingredients of IP and matched vehicle
- With coronary heart disease with myocardial infarction, coronary artery bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA) within 3 months prior to Screening visit
(1) Female subject of childbearing potential who:
- is lactating; or
- has positive pregnancy test result at eligibility checking; or
- refuses to adopt at least one form of birth control from signing informed consent to the end of study
Note:
Acceptable forms include:
Established use of oral, injected or implanted hormonal methods of contraception. Placement of an intrauterine device (IUD) or intrauterine system (IUS).Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault caps)
7(2) Male subject with female spouse/partners who are of childbearing potential refuses to adopt at least one form of birth control (at least one of which must be a barrier method) from signing informed consent to the end of study)
- With ankle brachial index (ABI) < 0.6
- Enrollment in any investigational drug trial within 4 weeks before entering this study
- With any condition judged by the investigator that entering the trial may be detrimental to the subject
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ENERGI-F703 GEL
topical application on target venous leg ulcer, twice daily
|
The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first. The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size. |
Placebo Comparator: ENERGI-F703 GEL matched vehicle
topical application on target venous leg ulcer, twice daily
|
The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first. The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of complete ulcer closure
Time Frame: Day -21 to Day 99
|
Complete wound closure is defined as 100% skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visit 2 weeks apart.
|
Day -21 to Day 99
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage change in target ulcer area from baseline to each post-treatment visit
Time Frame: Day -21 to Day 85
|
Day -21 to Day 85
|
|
Time-to-Complete ulcer closure of target ulcer
Time Frame: Day -21 to Day 99
|
Complete wound closure is defined as 100% skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visit 2 weeks apart.
|
Day -21 to Day 99
|
The accumulated confirmed target ulcer closure incidence at each of the post-treatment visit
Time Frame: Day -21 to Day 85
|
Complete wound closure is defined as 100% skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visit 2 weeks apart.
|
Day -21 to Day 85
|
Incidence of vital signs abnormalities
Time Frame: Day -21 to Day 169
|
Vital signs measurement will consist of systolic/diastolic blood pressure, respiratory rate, pulse rate or heart rate, and body temperature.
|
Day -21 to Day 169
|
Incidence of physical examination abnormalities
Time Frame: Day -21 to Day 169
|
Physical examination will include the following items: general appearance, skin, eyes, ears, nose, throat, head and neck, heart, chest and lungs, abdomen, extremities, lymph nodes, musculoskeletal, neurological and others.
|
Day -21 to Day 169
|
Incidence of laboratory examination results abnormalities
Time Frame: Day -21 to Day 169
|
The laboratory examinations include Hematology tests (CBC), Biochemistry (AST, ALP, ALT, serum creatinine, BUN, albumin and fasting glucose) and Urinalysis (pH, glucose, RBC, WBC and protein).
|
Day -21 to Day 169
|
Incidence of AEs and SAEs
Time Frame: Day -21 to Day 169
|
Day -21 to Day 169
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ENERGI-F703-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Leg Ulcer
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
DeRoyal Industries, Inc.Royal College of Surgeons, Ireland; Enterprise Ireland; Tyndall National InstituteCompletedVenous Leg Ulcer | Venous Insufficiency of LegIreland
-
Chang Gung Memorial HospitalRecruitingVenous Leg Ulcer | Venous Insufficiency of Leg | Venous Occlusion | Contrast Media ReactionTaiwan
-
Ortec InternationalCompletedVenous Leg Ulcer | Venous Stasis UlcerUnited States
-
Firstkind LtdTerminatedLeg Ulcer | Venous Leg Ulcer | Venous UlcerCanada
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States, Australia, Germany, Italy, United Kingdom, New Zealand, Ireland
-
Firstkind LtdCompletedLeg Ulcer | Venous Leg Ulcer | Wound | Wound Leg | Leg Ulcers VenousUnited Kingdom
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States
-
Mansoura UniversityActive, not recruitingVaricose Veins | Venous Insufficiency | Venous Leg Ulcer | Venous RefluxEgypt
Clinical Trials on ENERGI-F703 GEL
-
Energenesis Biomedical Co., Ltd.RecruitingDiabetes Mellitus | Foot Ulcer | Diabetic Foot Ulcer | WoundUnited States
-
Energenesis Biomedical Co., Ltd.A2 Healthcare Taiwan CorporationCompletedDiabetes Mellitus | Diabetic Foot | Foot Ulcer | WoundsTaiwan
-
Energenesis Biomedical Co., Ltd.A2 Healthcare Taiwan CorporationCompleted
-
Starpharma Pty LtdCompletedBacterial VaginosisUnited States
-
Glyciome, LLCBrigham and Women's Hospital; University of Puerto RicoCompletedSensory Perceptual Characteristics | User Acceptability of Gel Delivery SystemUnited States, Puerto Rico
-
Novan, Inc.CompletedAcne VulgarisDominican Republic, Honduras, Panama
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
NFlection Therapeutics, Inc.CompletedNeurofibromatosis 1 | Cutaneous NeurofibromaUnited States
-
Alcon ResearchCompleted
-
DermBiont, Inc.Active, not recruiting